Oncolytic Immunotherapy Virus

Doctors have long observed that certain viruses can slow the progression of cancer. Oncolytic immunotherapy aims to build on this potential by using genetically modified viruses to target tumors in two important and complementary ways.

By deleting certain viral genes, scientists can make viruses that can replicate effectively in tumor cells but not in normal cells. Tumor-selective viral replication can cause tumor cells to lyse, or burst open (oncolysis). The virus can also be modified to produce human signaling proteins that summon immune cells to the site of the lysed tumors, where they encounter tumor antigens. The aim is to generate a broad immunotherapeutic response that can help cytotoxic T cells to recognize and attack distant tumor metastases in the body.

Viruses can be harnessed as vectors for oncolytic immunotherapy. The virus can be modified by inserting, deleting, and/or inactivating various genes in order to achieve desired effects, including: • A virus that will replicate selectively in tumor cells but not healthy cells. • The ability to lyse, or burst, tumor cells to expose tumor antigens to the immune system. • A virus that can produce human signally proteins to summon immune cells to the site of the tumor and teach them to recognize and target tumors with similar antigen profiles.

Subscribe for the latest from Amgen Science.

System error message. Lorem ipsum.
I authorize Amgen and its contractors to use my email address and provide me with updates, informational material, and/or contact me about Amgen Science. I understand that my email address will not be used for any other purposes. I understand that receiving these communications is optional and free and that I have the ability to opt out at anytime. For more information, please see the Amgen privacy policy.